When Will Wegovy 7.2mg Be Available in the UK?

The misconception: 7.2mg is still waiting for approval

The most common reason people search this question is a reasonable one, news coverage lagged behind the regulatory timeline, and articles written in late 2025 described 7.2mg as pending. Those articles are out of date. The MHRA approved the higher dose initially in January 2026, when Novo Nordisk began supplying it as three 2.4mg pens per week. Then, on 14 April 2026, a purpose-built single-dose pen received its own authorisation: one injection, one dose, auto-locked after use. That is the pen most people now mean when they ask about Wegovy 7.2mg.

The MHRA's announcement on GOV.UK confirms both the approval date and the pen format. If you read anything suggesting you need to wait for a UK launch, check its publication date, the information is almost certainly from before April 2026.

Stock availability is a separate question from regulatory approval. Pharmacies order through the licensed UK supply chain, and supply of newer dose formats can be patchy in the early months. One practical check you can do right now: visit any online pharmacy's consultation page and look for whether 7.2mg appears as an option during assessment, or ask the pharmacy directly before you start, and our guide to Wegovy 7.2mg availability explains what to expect from different providers at the moment. That takes under a minute and gives you a concrete answer for that provider today.

Who the 7.2mg dose is licensed for, and where it sits in the titration schedule

The 7.2mg approval is not a blanket upgrade for everyone on semaglutide. Its licence specifically covers adults with a BMI of 30 or above for weight management. It is not authorised for the cardiovascular-risk indication, and it does not extend to lower BMI thresholds. So if 7.2mg suits your clinical picture depends on your BMI, your comorbidities and how you have tolerated the earlier doses.

Titration still starts at 0.25mg. The NHS medicines page for semaglutide explains the general dose-escalation approach: each step stays in place for roughly four weeks before a prescriber considers moving up. The prescriber's job is to balance tolerability against progress, moving too fast tends to make gastrointestinal side effects worse, not better. For detail on how the steps work in practice, the guide to increasing your Wegovy dose covers this thoroughly. The 7.2mg level is the ceiling, reached only after passing through 0.5mg, 1.0mg, 1.7mg and 2.4mg and being assessed at each point.

People who are already established on 2.4mg weekly and tolerating it well are the likeliest candidates for the step up to 7.2mg, but that step still requires clinical sign-off, not just a patient request. Trial data reported average weight loss of around 20.7% over 72 weeks at 7.2mg, which brings semaglutide's results closer to those seen with tirzepatide at its highest doses. That is a meaningful difference from the roughly 15% average seen in the STEP 1 trial at 2.4mg.

How the 7.2mg pen differs from earlier Wegovy pens

The earlier approach to delivering 7.2mg was, frankly, a workaround, patients took three separate 2.4mg pens in the same week, which introduced room for error and was inconvenient. The dedicated single-dose pen changes that: one injection per week, a fixed dose pre-loaded, with a mechanism that locks after use to prevent double-dosing. It does not need to be set by the patient. For people who found the multi-pen approach fiddly, this is a practical improvement.

Storage follows the same refrigeration requirement as other Wegovy pens. The exact window for leaving it at room temperature before use is specified in the Patient Information Leaflet, always defer to that rather than any general figure quoted online, since individual batch specifications can vary. For a full picture of the doses available in the Wegovy range and how each one fits into the treatment journey, our page on the Wegovy strengths currently available sets out each option clearly alongside what distinguishes them.

If you are weighing up the injectable against the new oral option, Novo Nordisk's Wegovy treatment overview covers both formats and the clinical differences between them, useful context if you are deciding which route suits you.

Getting access to Wegovy 7.2mg through a private clinic

On the NHS, Wegovy is available only through specialist weight management services under NICE's appraisal (TA875), and waiting lists in many areas are substantial. The 7.2mg dose is unlikely to be the first thing an NHS pathway offers, given that patients are typically managed through the full titration schedule over many months before reaching that level.

Private clinics and regulated online pharmacies are the practical route for most people right now. The legal requirement is identical regardless of where you get it: a prescription from a registered prescriber, issued after a genuine clinical assessment. Any route that offers semaglutide at this dose without that assessment is not a legitimate one. You can verify that any pharmacy you consider is GPhC-registered at the GPhC pharmacy register, the search takes moments and it is the clearest signal of legitimacy available.

For context on what private treatment typically costs at different dose levels, this breakdown of Wegovy pricing in the UK explains what drives the variation between providers and what a transparent price should include. If you are ready to see whether you are clinically suitable for Wegovy, including whether 7.2mg might eventually be appropriate for you, start your free consultation with our prescribers and get a same-day clinical review.